Cleansing Options in Out-Patient Setting to Improve Tolerance (COOP SIT) Trial

NCT ID: NCT07215000

Last Updated: 2025-10-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-10-01

Study Completion Date

2027-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research is to compare patient preferences for two bowel preparation options: low-volume tablets (Suflave/Sutab) versus the standard colon preparation using Golytely (polyethylene glycol). The study aims to enroll approximately 300 patients, who will be randomly assigned to one of the two preparation methods in a 2:1 ratio prior to their scheduled colonoscopy appointments. Surveys will be conducted both before and after the procedures.

This project will be conducted over a 12-month period and seeks to compare patient experience of both preparation methods in an outpatient setting. The study will evaluate the rate of preparation completion, patient satisfaction, tolerance of the solutions, and the endoscopic adequacy of each method.

Eligible participants are patients aged 18 or older with upcoming colonoscopy appointments who can provide informed consent in English or Spanish. There is no health risks associated with this study, as both bowel preparation methods are FDA-approved and commonly used in clinical practice.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer Screening Bowel Cleansing for Colonoscopy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Golytely

GoLYTELY is a prescription medicine used by adults to clean the colon before a colonoscopy or barium enema X-ray examination. GoLYTELY cleans your colon by causing you to have diarrhea (loose stools). Cleaning your colon helps your healthcare provider see the inside of your colon more clearly during your colonoscopy. Drink reconstituted solution at a rate of 8 ounces every 10 minutes, until 4 liters are consumed, or rectal effluent is clear.

Group Type ACTIVE_COMPARATOR

Golytely

Intervention Type DRUG

large volume liquid prep.

Sulfave

Suflave is a combination, osmotic prescription laxative that may be used to cleanse the bowel in preparation for colonoscopy in adults. Suflave contains polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride, and is supplied as a powder that is mixed with a low volume of water before consuming. It tastes like a lemon-lime sports drink. Drink 8 ounces of the solution every 15 minutes until the bottle is empty, and then drink an additional 16 ounces of water during the evening. One dose of Suflave is equal to one bottle plus one flavor-enhancing packet.

Group Type OTHER

Sulfave

Intervention Type DRUG

SUFLAVE is a split-dose (2-day) regimen. A total of 2 bottles are required for complete preparation for colonoscopy. You will take 2 bottles of liquid in two separate doses. One dose of SUFLAVE is equal to one bottle plus one flavor enhancing packet.

Sutab

SUTAB comes in a kit that contains two medication bottles and a cup for water. Each bottle contains 12 tablets (pills). You'll take 12 pills (one bottle) with water from the cup the night before your exam. Later that evening, drink two more cups of water. Fill the cup to the line each time. Then, six hours before your exam, repeat all three of those steps.

Group Type OTHER

Sutab

Intervention Type DRUG

SUTAB comes in a kit that contains two medication bottles and a cup for water. Each bottle contains 12 tablets (pills). You'll take 12 pills (one bottle) with water from the cup the night before your exam. Later that evening, drink two more cups of water. Fill the cup to the line each time. Then, six hours before your exam, repeat all three of those steps.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Golytely

large volume liquid prep.

Intervention Type DRUG

Sulfave

SUFLAVE is a split-dose (2-day) regimen. A total of 2 bottles are required for complete preparation for colonoscopy. You will take 2 bottles of liquid in two separate doses. One dose of SUFLAVE is equal to one bottle plus one flavor enhancing packet.

Intervention Type DRUG

Sutab

SUTAB comes in a kit that contains two medication bottles and a cup for water. Each bottle contains 12 tablets (pills). You'll take 12 pills (one bottle) with water from the cup the night before your exam. Later that evening, drink two more cups of water. Fill the cup to the line each time. Then, six hours before your exam, repeat all three of those steps.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

polyethylene glycol 3350 sodium sulfaten potassium chloride, magnesium sulfate

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults over age of 18 years undergoing outpatient colonoscopy for various indications, ability to consent in English or Spanish. Patients will still be allowed to join if there is a history of colorectal cancer or previous surgery

Exclusion Criteria

* Patient is less than 18 years of age, any pregnant or nursing women, unable to consent, or patient is incarcerated.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Morehouse School of Medicine

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jesus M Luevano, MD, MS

Role: PRINCIPAL_INVESTIGATOR

Morehouse School of Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Morehouse School of Medicine

Atlanta, Georgia, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Julia J Liu, MD, MSc

Role: CONTACT

(404) 756-1369

Tasha Rhymes, M.S. Ed.

Role: CONTACT

(404) 756-1369

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jesus Luevano, M.D.

Role: primary

404-971-9018

Julia Liu, M.D.

Role: backup

404-756-1389

References

Explore related publications, articles, or registry entries linked to this study.

Averous M. [Results of early surgery of obstructive uropathies diagnosed prenatally: apropos of 56 cases]. Acta Urol Belg. 1989;57(2):423-30. No abstract available. French.

Reference Type BACKGROUND
PMID: 2763922 (View on PubMed)

Niikawa N, Ishikiriyama S, Shikimani T. The "Michelin tire baby" syndrome--an autosomal dominant trait. Am J Med Genet. 1985 Nov;22(3):637-8. doi: 10.1002/ajmg.1320220327. No abstract available.

Reference Type BACKGROUND
PMID: 4061498 (View on PubMed)

Ito F, Harada Y. Responses of muscle spindle and leaflike receptor afferents to sinusoidal stretching. Am J Physiol. 1972 Nov;223(5):1246-9. doi: 10.1152/ajplegacy.1972.223.5.1246. No abstract available.

Reference Type BACKGROUND
PMID: 4265954 (View on PubMed)

Adamski GB, Garin EH, Ballinger WE, Shulman ST. Generalized nonsuppurative myositis with staphylococcal septicemia. J Pediatr. 1980 Apr;96(4):694-7. doi: 10.1016/s0022-3476(80)80745-1. No abstract available.

Reference Type BACKGROUND
PMID: 7359276 (View on PubMed)

Jaric MV. Long-range icosahedral orientational order and quasicrystals. Phys Rev Lett. 1985 Aug 5;55(6):607-610. doi: 10.1103/PhysRevLett.55.607. No abstract available.

Reference Type BACKGROUND
PMID: 10032399 (View on PubMed)

Vemulapalli KC, Lahr RE, Rex DK. 2021 Patient Perceptions Regarding Colonoscopy Experience. J Clin Gastroenterol. 2023 Apr 1;57(4):400-403. doi: 10.1097/MCG.0000000000001689.

Reference Type BACKGROUND
PMID: 35324481 (View on PubMed)

Chien C, Morimoto LM, Tom J, Li CI. Differences in colorectal carcinoma stage and survival by race and ethnicity. Cancer. 2005 Aug 1;104(3):629-39. doi: 10.1002/cncr.21204.

Reference Type BACKGROUND
PMID: 15983985 (View on PubMed)

Miller JS, Cervenka T, Lund J, Okazaki IJ, Moss J. Purine metabolites suppress proliferation of human NK cells through a lineage-specific purine receptor. J Immunol. 1999 Jun 15;162(12):7376-82.

Reference Type BACKGROUND
PMID: 10358189 (View on PubMed)

Wilson NI, Dreghorn CR. Costs of prophylaxis in joint prosthesis. Br Med J (Clin Res Ed). 1988 Feb 13;296(6620):499. No abstract available.

Reference Type BACKGROUND
PMID: 3126877 (View on PubMed)

Freer JH, Levinson HS. Fine structure of Bacillus megaterium during microcycle sporogenesis. J Bacteriol. 1967 Aug;94(2):441-57. doi: 10.1128/jb.94.2.441-457.1967.

Reference Type BACKGROUND
PMID: 4962705 (View on PubMed)

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.

Reference Type BACKGROUND
PMID: 36633525 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2282829

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.